22101-09-3

Basic information

• Product Name: 3-(4-chlorophenyl)-3-phenylpropionamide
• Synonyms: 3-(4-chlorophenyl)-3-phenylpropionamide
• CAS NO: 22101-09-3
• Molecular Weight: 259.735
• Mol File: 22101-09-3.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-chlorophenyl)-3-phenylpropionamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-chlorophenyl)-3-phenylpropionamide(22101-09-3)
• EPA Substance Registry System: 3-(4-chlorophenyl)-3-phenylpropionamide(22101-09-3)

Safety Data

• Hazardous Substances Data: 22101-09-3(Hazardous Substances Data)

Upstream product

• 1073-67-2 4-vinylbenzyl chloride 
• 21161-20-6 1-tert-butoxycarbonyl-2-(4'-chloro)phenylazetidine 
• 71-43-2 benzene 
• 18166-64-8 4-chlorocinnamide 
• 637-87-6 1-Chloro-4-iodobenzene 
• 621-79-4 cinnamamide 

Downstream Products

• 114667-10-6 3-(4-chlorophenyl)-3-phenylpropan-1-amine 

Relevant articles and documents

DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND 5-LIPOXYGENASE

The invention pertains to a novel structure (I) that provides an activity as a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LOX). The invention pertains to multiple derivatives of the new class of dual inhibitors, their application in medicine, pharmaceutical compositions comprising them as well as to methods for synthesizing the new compounds.

Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase

Inhibition of multiple enzymes of the arachidonic acid cascade leads to synergistic anti-inflammatory effects. Merging of 5-lipoxygenase (5-LOX) and soluble epoxide hydrolase (sEH) pharmacophores led to the discovery of a dual 5-LOX/sEH inhibitor, which was subsequently optimized in terms of potency toward both targets and metabolic stability. The optimized lead structure displayed cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrated profound anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice. These results pave the way for investigating the therapeutic potential of dual 5-LOX/sEH inhibitors in other inflammation- and fibrosis-related disease models.

The acid-mediated ring opening reactions of α-aryl-lactams

4-Aryl-azetidin-2-ones (β-lactams) undergo ring opening with triflic acid to give cinnamamides which, in benzene, react further to give 3-aryl-3-phenyl-propionamides. Prolonged reaction times in benzene give 3,3-diphenyl-propionamide via an aryl/phenyl ex